News
03-24-2010, 05:20 AM
Garnet BioTherapeutics, Inc. ("Garnet"), a regenerative medicine company focused on developing cell based therapies, announced that the first patient has been treated in a Phase 2 multicenter, double-blind, placebo-controlled study of its lead product candidate GBT009 at Unity Hospital in Rochester, New York...
More... (http://mnt.to/f/3zmh)
More... (http://mnt.to/f/3zmh)